drugset / Trial / NCT05415241
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
Phase 1/2
Unknown
60 enrolled
Ruijin Hospital
Frontier Biotechnologies Inc. · collabShanghai Center for Disease Control and Prevention · collab
NaSequentialOpen-labelPrevention
Summary
This is a single-arm, open-label, dose ramp-up exploratory clinical trial to evaluate the efficacy, safety and tolerance of aerosol inhalation of FB2001 as post-exposure prophylaxis among close contacts of COVID-19 patients. This study will enroll 20 to 60 close contacts of COVID-19 patients aging 18 to 65 years. After signing the informed consent form, the qualified subjects will be given FB2001 once or twice daily.
Timeline
- Start
- 2022-06-09
- Primary completion
- 2022-08-09
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FB2001 | Small molecule | — | Inhaled |
Indications
No indication recorded.